11/9
02:07 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/7
07:18 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News [Yahoo! Finance]
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News [Yahoo! Finance]
11/5
09:11 am
agio
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
Medium
Report
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
11/5
09:05 am
agio
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
Medium
Report
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
11/1
11:06 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/1
12:38 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
11/1
10:34 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Scotiabank from $51.00 to $53.00. They now have a "sector outperform" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Scotiabank from $51.00 to $53.00. They now have a "sector outperform" rating on the stock.
11/1
09:18 am
agio
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
10/31
06:30 am
agio
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
Medium
Report
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
10/23
07:00 am
agio
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
Low
Report
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
10/17
07:00 am
agio
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
Low
Report
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
10/16
11:05 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/16
08:44 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/10
09:36 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $51.00 price target on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $51.00 price target on the stock.
9/28
07:43 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
9/27
07:41 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $56.00 price target on the stock, down previously from $60.00.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $56.00 price target on the stock, down previously from $60.00.
9/20
11:09 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/19
09:21 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
9/17
08:07 am
agio
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results [Yahoo! Finance]
9/14
08:44 am
agio
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth [Yahoo! Finance]
Low
Report
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth [Yahoo! Finance]
9/12
06:54 am
agio
Agios Pharmaceuticals' tebapivat gains FDA orphan drug designation [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals' tebapivat gains FDA orphan drug designation [Yahoo! Finance]
9/11
07:00 am
agio
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
Low
Report
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
9/5
07:00 am
agio
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
Medium
Report
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024